Motus GI Stock Surges On FDA Approval For Next-Gen Pure-Vu EVS System
The FDA has granted 510(k) clearance to Motus GI Holdings Inc's (NASDAQ: MOTS) upgraded Pure-Vu EVS System.
The new Pure-Vu EVS System is intended to improve the speed of set-up, enhance navigation capabilities in tortuous anatomy, build upon the Pure-Vu system's cleansing capabilities, and enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy.
The Pure-Vu platform facilitates the cleaning of a poorly prepared colon to improve visualization during the colonoscopy procedure.
The platform integrates with standard and slim colonoscopes and preserves established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam.
The new Pure-Vu EVS is designed to offer significant usability advancements over the currently marketed device, including enhanced physician navigation and control, on-demand bedside loading, expanded cleansing capacity, and a smaller workstation footprint.
The commercial launch of the Pure-Vu EVS in Q1 of 2022.
Price Action: MOTS shares are up 37.60% at $0.58 during the premarket session on the last check Monday.
See more from Benzinga
Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.